With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its commercial operations. Three weeks into taking on the role of Lexicon Pharmaceuticals CEO back in 2024, Michael Exton told Fierce the company close its commercial operations. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events…

Source: FierceBiotech